QUOTE (Frangible @ Apr 18 2008, 02:49 PM)

It's certainly tricky/interesting. It can be in our head, certainly. But the enteric nervous system is pretty huge mass of reptilian intelligence unto itself-- it has more neurons than the spinal cord.
So wait. Anxiety should elevate NE and decrease bloating/diarrhea, not increase it. This makes sense, since you don't really need to feel an overwhelming desire to take a crap when a bear/velociraptor/zombie is chasing you.
Haven't you heard that when (if) a bear/velociraptor/zombie is chasing you, some may
shit themselves ... for real, I shit you not.
You brought the allergies thing, compromised immune systems are prone to asthma, food allergies, eczema, IBS all because we don't let kids eat a little dirt now and then. You see, in the developed world we are too clean, our gut flora is worked overtime and in some cases it is severely lacking.
*************************
Paediatr Perinat Epidemiol. 2007 Nov;21 Suppl 3:23-8.
Links Examining the hygiene hypothesis: the Trial of Infant Probiotic Supplementation. Cabana MD,
McKean M,
Wong AR,
Chao C,
Caughey AB. Department of Pediatrics, University of California, San Francisco, CA 94118, USA. michael.cabana@ucsf.edu
The hygiene hypothesis suggests that the absence of infectious exposure at a critical point in immune system development leads to a greater risk for the later development of atopic disease. As a result, it may be possible to devise strategies that can block the onset of atopic diseases such as asthma. This paper outlines the rationale, background and design for the Trial of Infant Probiotic Supplementation study, which is designed to test the effectiveness of a daily infant probiotic supplement in the first 6 months of life in preventing the development of early markers of asthma.
PMID: 17935572
************************************
Adv Exp Med Biol. 2008;606:423-54.
Links Probiotics, immunomodulation, and health benefits. Gill H,
Prasad J. Department of Primary Industries, Werribee, Victoria 3030, Australia. Harsharn.Gill@dpi.vic.gov.au
Probiotics are defined as live microorganisms that, when administered in adequate amount, confer a health benefit on the host. Amongst the many benefits associated with the consumption of probiotics, modulation of the immune system has received the most attention. Several animal and human studies have provided unequivocal evidence that specific strains of probiotics are able to stimulate as well as regulate several aspects of natural and acquired immune responses. There is also evidence that intake of probiotics is effective in the prevention and/or management of acute gastroenteritis and rotavirus diarrhoea, antibiotic-associated diarrhoea and intestinal inflammatory disorders such as Crohn's disease and pouchitis, and paediatric atopic disorders. The efficacy of probiotics against bacterial infections and immunological disorders such as adult asthma, cancers, diabetes, and arthritis in humans remains to be proven. Also, major gaps exist in our knowledge about the mechanisms by which probiotics modulate immune function. Optimum dose, frequency and duration of treatment required for different conditions in different population groups also remains to be determined. Different probiotic strains vary in their ability to modulate the immune system and therefore efficacy of each strain needs to be carefully demonstrated through rigorously designed (randomised, double-blind, placebo-controlled) studies. This chapter provides an over view of the immunomodulatory effects of probiotics in health and disease, and discusses possible mechanisms through which probiotics mediate their disparate effects.
PMID: 18183940
******************************
Allergy. 2007 Nov;62(11):1223-36. Epub 2007 Aug 17.
Links The role of the intestinal microbiota in the development of atopic disorders. Penders J,
Stobberingh EE,
van den Brandt PA,
Thijs C. Department of Epidemiology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University, Maastricht, The Netherlands.
The prevalence of atopic diseases, including eczema, allergic rhinoconjunctivitis and asthma, has increased worldwide, predominantly in westernized countries. Recent epidemiological studies and experimental research suggest that microbial stimulation of the immune system influences the development of tolerance to innocuous allergens. The gastrointestinal microbiota composition may be of particular interest, as it provides an early and major source of immune stimulation and seems to be a prerequisite for the development of oral tolerance. In this review the observational studies of the association between the gut microbiota and atopic diseases are discussed. Although most studies indicated an association between the gut microbiota composition and atopic sensitization or symptoms, no specific harmful or protective microbes can be identified yet. Some important methodological issues that have to be considered are the microbiological methods used (traditional culture vs molecular techniques), the timing of examining the gut microbiota, the definition of atopic outcomes, confounding and reverse causation.
In conclusion, the microbiota hypothesis in atopic diseases is promising and deserves further attention. To gain more insight into the role of the gut microbiota in the etiology of atopy, large-scale prospective birth cohort studies using molecular methods to study the gut microbiota are needed.
PMID: 17711557
******************************
Pharmacotherapy. 2008 Apr;28(4):496-505.
Links Effectiveness of probiotics in the treatment of irritable bowel syndrome. Wilhelm SM,
Brubaker CM,
Varcak EA,
Kale-Pradhan PB. 1 Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Harper University Hospital, Detroit, Michigan.
Abstract Recently, the use of tegaserod and alosetron-drugs approved for the treatment of irritable bowel syndrome (IBS)-has been restricted because of adverse events. This has resulted in a need for additional modalities for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit time, and bacterial counts. Using the MEDLINE database from 1966-October 2007 and manually searching article references for relevant articles and abstracts, we identified 14 blinded, placebo-controlled clinical trials of the effectiveness of probiotics in the treatment of IBS. Of 11 studies in which overall symptom relief was assessed, seven indicated a significant improvement with probiotics versus placebo. Five of eight investigations of abdominal pain and distention revealed a benefit with probiotic use. Four studies demonstrated an improvement in symptomatic flatulence in probiotic treatment groups, whereas one study showed no significant benefit. Four of five studies of the effects of probiotics on colonic transit time revealed a benefit compared with placebo.
As probiotics have shown benefit and possess a favorable adverse-effect profile, their use may represent an option for symptom relief in patients with IBS. However, additional data are necessary before probiotics can become a standard of care in the treatment of IBS, a complex and chronic condition.
PMID: 18363533
******************************
Behav Res Ther. 2001 Jul;39(7):801-11.
Links The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Keefer L,
Blanchard EB. The University at Albany, State University of New York, Center for Stress and Anxiety Disorders, 12203, USA.
In this study, Herbert Benson's (1975) Relaxation Response Meditation program was tested as a possible treatment for Irritable Bowel Syndrome (IBS). Participants were 16 adults who were matched into pairs based on presence of Axis I disorder, primary IBS symptoms and demographic features and randomized to either a six week meditation condition or a six week wait list symptom monitoring condition. Thirteen participants completed treatment and follow-up. All subjects assigned to the Wait List were subsequently treated. Patients in the treatment condition were taught the meditation technique and asked to practice it twice a day for 15 minutes. Composite Primary IBS Symptom Reduction (CPSR) scores were calculated for each patient from end of baseline to two weeks post-treatment (or to post wait list). One tailed independent sample t-tests revealed that Meditation was superior to the control (P=0.04). Significant within-subject improvements were noted for flatulence (P=0.03) and belching (P=0.02) by post-treatment. By three month follow-up, significant improvements in flatulence (P<0.01), belching (P=0.02), bloating (P=0.05), and diarrhea (P=0.03) were shown by symptom diary. Constipation approached significance (P=0.07). Benson's Relaxation Response Meditation appears to be a viable treatment for IBS.
PMID: 11419611
***********************************
In other words...Buddha didn't get IBS